Published in Br J Haematol on September 11, 2006
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
The molecular biology of mixed lineage leukemia. Haematologica (2009) 2.58
The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 2.55
Etoposide-initiated MLL rearrangements detected at high frequency in human primitive hematopoietic stem cells with in vitro and in vivo long-term repopulating potential. Eur J Haematol (2008) 2.15
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res (2010) 1.73
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica (2010) 1.71
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood (2007) 1.64
Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol (2011) 1.33
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet (2015) 1.03
Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification. Dtsch Arztebl Int (2008) 1.02
High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis. Oncotarget (2015) 0.87
Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn (2009) 0.85
Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev (2015) 0.83
Is it important to decipher the heterogeneity of "normal karyotype AML"? Best Pract Res Clin Haematol (2008) 0.81
A mechanism of gene amplification driven by small DNA fragments. PLoS Genet (2012) 0.81
Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies. BMC Genomics (2013) 0.77
Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. Blood (2016) 0.76
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr (2017) 0.75
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. Clin Lymphoma Myeloma Leuk (2014) 0.75
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol (2010) 3.88
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul (2006) 3.32
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol (2010) 2.31
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood (2003) 1.65
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest (2007) 1.63
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol (2006) 1.25
The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer (2010) 1.13
CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle (2007) 1.12
Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (2002) 1.09
The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets (2004) 1.03
The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets (2005) 1.02
AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation. Leuk Lymphoma (2005) 0.99
Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle (2005) 0.98
Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem (2009) 0.97
Label-free classification of cultured cells through diffraction imaging. Biomed Opt Express (2011) 0.90
Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom (2005) 0.90
Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?. Dermatology (2012) 0.86
Interpreting clinical trials in lung cancer: impact of methodology and endpoints. J Thorac Oncol (2007) 0.86
Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia. Blood (2002) 0.85
Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Br J Haematol (2008) 0.84
Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer (2007) 0.84
MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer (2012) 0.84
Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res (2003) 0.83
Chromosomal analysis and identification based on optical tweezers and Raman spectroscopy. Opt Express (2006) 0.83
Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adults. Leuk Res (2006) 0.83
Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol (2002) 0.83
Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 cases. J Cancer Res Clin Oncol (2014) 0.80
Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle (2005) 0.80
Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency. Haematologica (2011) 0.80
Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells. Cell Cycle (2005) 0.79
B-cell chronic lymphocytic leukemia with aberrant CD8 expression: genetic and immunophenotypic analysis of prognostic factors. Leuk Lymphoma (2004) 0.79
ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica (2004) 0.79
High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol (2007) 0.79
Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. Ann Hematol (2014) 0.78
Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer. Respiration (2013) 0.78
Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res (2002) 0.77
Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. J Cancer Res Clin Oncol (2012) 0.75
Upping the bid on engineered inducible cell death. Cancer Biol Ther (2005) 0.75
Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. Cell Cycle (2005) 0.75
[Surgery and adjuvant therapy in non-small-cell lung carcinoma (NSCLC). (stage I through operable stage IIIA)]. Onkologie (2006) 0.75
Immunophenotypic and genetic characterization of a CD8 positive mantle cell lymphoma in a patient with concomitant Mycosis fungoides. Eur J Haematol (2005) 0.75
[Local and systemic therapy of non-small cell lung carcinoma (NSCLC)]. Onkologie (2010) 0.75
Chloroma of pancreas-initial manifestation of a secondary leukemia after stem cell transplantation case report and review of the literature. J Gastrointest Surg (2013) 0.75
[Current Aspects of Diagnosis and Treatment of Lung Cancer]. Dtsch Med Wochenschr (2017) 0.75
[Pillnitz interdisciplinary discussion--summary]. Onkologie (2006) 0.75
[Tumor Conference I]. Onkologie (2013) 0.75
[Early staging in non-small cell lung cancer]. Onkologie (2012) 0.75
Chromosomal analysis and identification based on optical tweezers and Raman spectroscopy: reply. Opt Express (2007) 0.75
[Thoracic oncology - optimization through integrated approaches, quality assurance, and molecular biology. Forward]. Onkologie (2012) 0.75
[Foreword]. Onkologie (2008) 0.75
[Structures and ways of decision making in thoracic oncology: foreword]. Onkologie (2013) 0.75